2008
DOI: 10.1007/s10620-008-0646-7
|View full text |Cite
|
Sign up to set email alerts
|

Sildenafil, an Inhibitor of Phosphodiesterase Subtype 5, Prevents Indomethacin-Induced Small-Intestinal Ulceration in Rats via a NO/cGMP-Dependent Mechanism

Abstract: We examined the effect of sildenafil, an inhibitor of phosphodiesterase subtype 5, that catalyzes hydrolysis of 3',5'-cyclic guanosine monophosphate (cGMP), on indomethacin-induced small-intestinal ulceration in rats and investigated the mechanism of this action, especially in relation to endogenous nitric oxide (NO). Animals without fasting were given indomethacin (10 mg/kg) s.c. and then killed 24 h later. Indomethacin produced hemorrhagic lesions in the small intestine, accompanied by a promotion of enterob… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

1
27
0
1

Year Published

2011
2011
2020
2020

Publication Types

Select...
6

Relationship

0
6

Authors

Journals

citations
Cited by 26 publications
(29 citation statements)
references
References 31 publications
1
27
0
1
Order By: Relevance
“…3,5) The small intestines were excised, washed and fixed in 10% formalin solution, and the area of the intestinal ulcerogenic lesions was observed in digital photographs and Image J. The lesion area is expressed as a percentage of the total area of small intestine.…”
Section: Evaluation Of Gastric Mucosal Lesionsmentioning
confidence: 99%
See 4 more Smart Citations
“…3,5) The small intestines were excised, washed and fixed in 10% formalin solution, and the area of the intestinal ulcerogenic lesions was observed in digital photographs and Image J. The lesion area is expressed as a percentage of the total area of small intestine.…”
Section: Evaluation Of Gastric Mucosal Lesionsmentioning
confidence: 99%
“…Gastrointestinal lesions are the most common side effect in patients taking IMC, and RA patients taking IMC are more susceptible to IMC-induced gastric lesions in comparison with other patients. [3][4][5][6][7]9) Therefore, the development of IMC formulations that do not cause gastrointestinal lesions is highly anticipated. In this study, we designed new oral formulations containing IMC solid nanoparticles, and investigated their usefulness by evaluating drug bioavailability and the toxicity (gastric and small intestinal ulcerogenic responses to IMC).…”
Section: Rna Preparationmentioning
confidence: 99%
See 3 more Smart Citations